vs
ASP Isotopes Inc.（ASPI）与Ceribell, Inc.（CBLL）财务数据对比。点击上方公司名可切换其他公司
Ceribell, Inc.的季度营收约是ASP Isotopes Inc.的1.5倍（$24.8M vs $16.7M），Ceribell, Inc.自由现金流更多（$-11.0M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Ceribell, Inc.是一家专注于神经诊断领域的医疗科技企业，主打便携式快速脑电图检测设备，可为急症、重症护理场景提供便捷的癫痫发作监测解决方案，核心市场覆盖北美地区，目前正逐步推进全球化业务布局。
ASPI vs CBLL — 直观对比
营收规模更大
CBLL
是对方的1.5倍
$16.7M
自由现金流更多
CBLL
多$36.5M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $24.8M |
| 净利润 | — | $-13.5M |
| 毛利率 | 12.5% | 87.3% |
| 营业利润率 | — | -58.9% |
| 净利率 | — | -54.6% |
| 营收同比 | 1295.7% | — |
| 净利润同比 | -586.8% | — |
| 每股收益（稀释后） | — | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPICBLL
| Q4 25 | $16.7M | $24.8M | ||
| Q3 25 | $4.9M | $22.6M | ||
| Q2 25 | — | $21.2M | ||
| Q1 25 | — | $20.5M | ||
| Q3 24 | — | $17.2M |
净利润ASPICBLL
| Q4 25 | — | $-13.5M | ||
| Q3 25 | $-12.9M | $-13.5M | ||
| Q2 25 | — | $-13.6M | ||
| Q1 25 | — | $-12.8M | ||
| Q3 24 | — | $-10.4M |
毛利率ASPICBLL
| Q4 25 | 12.5% | 87.3% | ||
| Q3 25 | 8.7% | 88.3% | ||
| Q2 25 | — | 88.1% | ||
| Q1 25 | — | 87.9% | ||
| Q3 24 | — | 87.3% |
营业利润率ASPICBLL
| Q4 25 | — | -58.9% | ||
| Q3 25 | -306.1% | -64.8% | ||
| Q2 25 | — | -70.5% | ||
| Q1 25 | — | -69.3% | ||
| Q3 24 | — | -57.8% |
净利率ASPICBLL
| Q4 25 | — | -54.6% | ||
| Q3 25 | -263.7% | -59.6% | ||
| Q2 25 | — | -64.4% | ||
| Q1 25 | — | -62.4% | ||
| Q3 24 | — | -60.6% |
每股收益（稀释后）ASPICBLL
| Q4 25 | — | $-0.35 | ||
| Q3 25 | $-0.15 | $-0.37 | ||
| Q2 25 | — | $-0.38 | ||
| Q1 25 | — | $-0.36 | ||
| Q3 24 | — | $-1.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $159.3M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $155.3M |
| 总资产 | $498.0M | $195.8M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPICBLL
| Q4 25 | $333.3M | $159.3M | ||
| Q3 25 | $113.9M | $168.5M | ||
| Q2 25 | — | $177.4M | ||
| Q1 25 | — | $182.7M | ||
| Q3 24 | — | $14.1M |
总债务ASPICBLL
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
股东权益ASPICBLL
| Q4 25 | $204.2M | $155.3M | ||
| Q3 25 | $74.1M | $164.1M | ||
| Q2 25 | — | $172.2M | ||
| Q1 25 | — | $180.9M | ||
| Q3 24 | — | $-136.0M |
总资产ASPICBLL
| Q4 25 | $498.0M | $195.8M | ||
| Q3 25 | $225.9M | $199.5M | ||
| Q2 25 | — | $207.7M | ||
| Q1 25 | — | $213.5M | ||
| Q3 24 | — | $47.1M |
负债/权益比ASPICBLL
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-10.8M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-11.0M |
| 自由现金流率自由现金流/营收 | -284.7% | -44.2% |
| 资本支出强度资本支出/营收 | 57.9% | 0.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-41.6M |
8季度趋势，按日历期对齐
经营现金流ASPICBLL
| Q4 25 | $-37.8M | $-10.8M | ||
| Q3 25 | $-8.9M | $-11.1M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | — | $-11.4M | ||
| Q3 24 | — | — |
自由现金流ASPICBLL
| Q4 25 | $-47.4M | $-11.0M | ||
| Q3 25 | $-12.0M | $-11.5M | ||
| Q2 25 | — | $-7.6M | ||
| Q1 25 | — | $-11.6M | ||
| Q3 24 | — | — |
自由现金流率ASPICBLL
| Q4 25 | -284.7% | -44.2% | ||
| Q3 25 | -245.5% | -50.8% | ||
| Q2 25 | — | -35.9% | ||
| Q1 25 | — | -56.4% | ||
| Q3 24 | — | — |
资本支出强度ASPICBLL
| Q4 25 | 57.9% | 0.7% | ||
| Q3 25 | 64.4% | 1.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.7% | ||
| Q3 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
